Alps Advisors Inc Mirati Therapeutics, Inc. Transaction History

Alps Advisors Inc

$14.8 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$36.54 - $54.26 $22,106 - $32,827	-605 Reduced 1.56%	38,235 $1.42 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $349,185 - $834,423	8,461 Added 27.85%	38,840 $1.76 Million
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $152,082 - $221,605	-2,556 Reduced 7.76%	30,379 $2.12 Million
Q2 2022 Aug 11, 2022	BUY	$39.16 - $88.71 $1.29 Million - $2.92 Million	32,935 New	32,935 $2.21 Million
Q4 2020 Feb 03, 2021	SELL	$162.05 - $240.27 $9.21 Million - $13.7 Million	-56,836 Closed	0 $0
Q3 2020 Nov 04, 2020	SELL	$113.26 - $167.27 $305,122 - $450,625	-2,694 Reduced 4.53%	56,836 $9.44 Million
Q2 2020 Aug 05, 2020	SELL	$72.01 - $120.39 $1.26 Million - $2.1 Million	-17,470 Reduced 22.69%	59,530 $6.8 Million
Q1 2020 May 06, 2020	SELL	$69.78 - $116.21 $171,379 - $285,411	-2,456 Reduced 3.09%	77,000 $5.92 Million
Q4 2019 Feb 07, 2020	BUY	$70.76 - $128.86 $76,137 - $138,653	1,076 Added 1.37%	79,456 $10.2 Million
Q3 2019 Nov 04, 2019	BUY	$77.91 - $109.6 $247,520 - $348,199	3,177 Added 4.22%	78,380 $6.11 Million
Q2 2019 Aug 07, 2019	SELL	$59.49 - $104.71 $430,172 - $757,158	-7,231 Reduced 8.77%	75,203 $7.75 Million
Q1 2019 May 01, 2019	BUY	$43.65 - $78.95 $318,208 - $575,545	7,290 Added 9.7%	82,434 $6.04 Million
Q4 2018 Feb 04, 2019	BUY	$32.0 - $47.43 $572,192 - $848,095	17,881 Added 31.23%	75,144 $3.19 Million
Q3 2018 Oct 25, 2018	BUY	$47.1 - $62.7 $711,398 - $947,020	15,104 Added 35.83%	57,263 $2.7 Million
Q2 2018 Aug 02, 2018	BUY	$26.05 - $52.4 $1.1 Million - $2.21 Million	42,159 New	42,159 $2.08 Million

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Account